Adrian Towse

Names

Identifer

Contact

Affiliations

• Office of Health Economics
  • EDIRC entry
  • location:

Research profile

author of:

• An Ambitious USG Advanced Commitment for Subscription-Based Purchasing of Novel Antimicrobials and Its Expected Return on Investment (RePEc:cgd:ppaper:277)
  by Adrian Towse & Rachel Silverman Bonnifield
• The Future of Global Health Procurement: Issues around Pricing Transparency (RePEc:cgd:wpaper:507)
  by Mikel Berdud & Kalipso Chalkidou & Emma Dean & Jimena Ferraro & Lou Garrison & Cassandra Nemzoff & Adrian Towse
• Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation (RePEc:eee:hepoli:v:121:y:2017:i:10:p:1025-1030)
  by Towse, Adrian & Hoyle, Christopher K. & Goodall, Jonathan & Hirsch, Mark & Mestre-Ferrandiz, Jorge & Rex, John H.
• Is disease management relevant in Europe: some evidence from the United Kingdom (RePEc:eee:hepoli:v:48:y:1999:i:1:p:69-77)
  by Mason, Anne & Drummond, Michael & Towse, Adrian
• Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases (RePEc:hal:journl:hal-03710938)
  by Dimitrios Kourouklis & Mikel Berdud & Mireia Jofre-Bonet & Adrian Towse
• Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement (RePEc:nbr:nberwo:17174)
  by Patricia M. Danzon & Andrew W. Mulcahy & Adrian K. Towse
• Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context (RePEc:nbr:nberwo:18593)
  by Patricia M. Danzon & Adrian K. Towse & Jorge Mestre-Ferrandiz
• Unknown item RePEc:ohe:briefg:000075 (paper)
• The Market for Biosimilars: Evolution and Policy Options (RePEc:ohe:briefg:000238)
  by Deven Chauhan;Jorge Mestre-Ferrandiz;Adrian Towse
• Three Challenges to Achieving Better Analysis for Better Decisions: Generalisability, Complexity and Thresholds (RePEc:ohe:briefg:000267)
  by Martin Buxton;Adrian Towse
• Regulating Prices Paid by the NHS for Medicines Supplied by the UK-Based Pharmaceutical Industry (RePEc:ohe:briefg:000427)
  by Martin Cave;Adrian Towse
• From Efficacy to Cost-Effectiveness (RePEc:ohe:briefg:000438)
  by Michael F. Drummond;Adrian Towse
• Reducing Harm to Patients in the National Health Service. Will the Government’s Compensation Proposals Help? (RePEc:ohe:briefg:000484)
  by Paul Fenn;Alastair Gray;Neil Rickman;Rodrigo Salinas;Adrian Towse
• How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes? (RePEc:ohe:briefg:001740)
  by Amanda Cole;Adrian Towse;Michelle Mujoomdar;Arnold Chan;Franz Pichler
• Unknown item RePEc:ohe:briefg:001835 (paper)
• Unknown item RePEc:ohe:briefg:001836 (paper)
• Unknown item RePEc:ohe:briefg:001837 (paper)
• Unknown item RePEc:ohe:briefg:001838 (paper)
• Incentives for New Drugs to Tackle Anti-Microbial Resistance (RePEc:ohe:briefg:001842)
  by Adrian Towse;Jimena Ferraro;Jorge Mestre-Ferrandiz
• Unknown item RePEc:ohe:briefg:001851 (paper)
• Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help? (RePEc:ohe:briefg:001922)
  by Margherita Neri;Adrian Towse
• Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward (RePEc:ohe:briefg:002084)
  by Margherita Neri;Adrian Towse;Martina Garau
• Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication? (RePEc:ohe:briefg:002165)
  by Amanda Cole;Adrian Towse;Bernarda Zamora
• Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación? (RePEc:ohe:briefg:002176)
  by Amanda Cole;Adrian Towse;Bernarda Zamora
• Unknown item RePEc:ohe:conrep:000050 (paper)
• Unknown item RePEc:ohe:conrep:000192 (paper)
• Unknown item RePEc:ohe:conrep:000212 (paper)
• Unknown item RePEc:ohe:conrep:000234 (paper)
• Unknown item RePEc:ohe:conrep:000265 (paper)
• Unknown item RePEc:ohe:conrep:001660 (paper)
• Unknown item RePEc:ohe:conrep:001699 (paper)
• Unknown item RePEc:ohe:conrep:001743 (paper)
• Unknown item RePEc:ohe:conrep:001748 (paper)
• Unknown item RePEc:ohe:conrep:001784 (paper)
• Unknown item RePEc:ohe:conrep:001802 (paper)
• Unknown item RePEc:ohe:conrep:001944 (paper)
• Unknown item RePEc:ohe:conrep:001978 (paper)
• The R&D Cost of a New Medicine (RePEc:ohe:monogr:000135)
  by Jorge Mestre-Ferrandiz;Jon Sussex;Adrian Towse
• New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options (RePEc:ohe:monogr:000184)
  by Priya Sharma;Adrian Towse
• Biosimilars: How Much Entry and Price Competition Will Result? (RePEc:ohe:monogr:000195)
  by Adrian Towse;Nancy Mattison;Jorge Mestre-Ferrandiz
• Unknown item RePEc:ohe:monogr:000242 (paper)
• Economic Post-Launch Studies: Matching the Desirable with the Feasible (RePEc:ohe:monogr:000268)
  by Anne R. Mason;Michael F. Drummond;Adrian Towse
• Financing Health Care in the UK: A Discussion of NERA’s Prototype Model to Replace the NHS (RePEc:ohe:monogr:000409)
  by Adrian Towse
• Industrial Policy and the Pharmaceutical Industry (RePEc:ohe:monogr:000414)
  by Adrian Towse
• Value of the Pharmaceutical Industry to the UK Economy (RePEc:ohe:monogr:000415)
  by David Hale;Adrian Towse
• Guidelines for the Economic Evaluation of Pharmaceuticals: Can the UK learn from Australia and Canada? (RePEc:ohe:monogr:000423)
  by Adrian Towse
• Disease Management, the NHS and the Pharmaceutical Industry (RePEc:ohe:monogr:000446)
  by Anne R. Mason;Michael F. Drummond;Adrian Towse
• Cost-Effectiveness Thresholds: Economic and ethical issues (RePEc:ohe:monogr:000473)
  by Clive Pritchard;Nancy Devlin;Adrian Towse
• Influencing Prescribing in a Primary Care Led NHS (RePEc:ohe:monogr:000476)
  by Anne R. Mason;Michael F. Drummond;Jonathan Cooke;Adrian Towse
• Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty (RePEc:ohe:monogr:000479)
  by Hannah Kettler;Adrian Towse
• How Should the World Pay for a COVID-19 Vaccine? (RePEc:ohe:monogr:002287)
  by Adrian Towse
• Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold (RePEc:ohe:occpap:000106)
  by Adrian Towse;Paul Barnsley;Sarah Karlsberg-Schaffer;Jon Sussex
• The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation? (RePEc:ohe:occpap:000167)
  by Lou Garrison;Ruth Puig-Peiro;Adrian Towse
• Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution? (RePEc:ohe:occpap:000191)
  by Patricia Danzon;Martina Garau;Adrian Towse
• New Drugs to Tackle Antimicrobial Resistance: EU Policy Options (RePEc:ohe:occpap:000216)
  by Priya Sharma;Adrian Towse
• Comparative and Relative Effectiveness: A Challenge For Health Systems, Regulators, or Pharmaceutical Companies? (RePEc:ohe:occpap:001561)
  by Adrian Towse
• Unknown item RePEc:ohe:occpap:001600 (paper)
• Unknown item RePEc:ohe:respap:000037 (paper)
• Unknown item RePEc:ohe:respap:000160 (paper)
• Unknown item RePEc:ohe:respap:000177 (paper)
• Unknown item RePEc:ohe:respap:000188 (paper)
• Unknown item RePEc:ohe:respap:000211 (paper)
• Unknown item RePEc:ohe:respap:001764 (paper)
• Unknown item RePEc:ohe:respap:001811 (paper)
• Unknown item RePEc:ohe:respap:001848 (paper)
• Unknown item RePEc:ohe:respap:001997 (paper)
• Unknown item RePEc:ohe:respap:001998 (paper)
• Multi-indication Pricing: Pros, Cons and Applicability to the UK (RePEc:ohe:sembri:001653)
  by Jorge Mestre-Ferrandiz;Renato Dellamano;Michele Pistollato;Adrian Towse
• Fostering incentives for research, development, and delivery of interventions for neglected tropical diseases: lessons from malaria (RePEc:oup:oxford:v:32:y:2016:i:1:p:64-87.)
  by Mikel Berdud & Adrian Towse & Hannah Kettler
• Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al (RePEc:sae:medema:v:41:y:2021:i:3:p:255-257)
  by Chris Sampson & Isobel Firth & Adrian Towse
• Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy (RePEc:spr:aphecp:v:20:y:2022:i:5:d:10.1007_s40258-022-00730-3)
  by Chris Sampson & Bernarda Zamora & Sam Watson & John Cairns & Kalipso Chalkidou & Patricia Cubi-Molla & Nancy Devlin & Borja García-Lorenzo & Dyfrig A. Hughes & Ashley A. Leech & Adrian Towse
• Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe? (RePEc:spr:eujhec:v:13:y:2012:i:1:p:1-5)
  by Michael Drummond & Adrian Towse
• Orphan drugs policies: a suitable case for treatment (RePEc:spr:eujhec:v:15:y:2014:i:4:p:335-340)
  by Michael Drummond & Adrian Towse
• Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare (RePEc:spr:eujhec:v:20:y:2019:i:3:d:10.1007_s10198-018-1007-x)
  by Bengt Jönsson & Grace Hampson & Jonathan Michaels & Adrian Towse & J.-Matthias Graf Schulenburg & Olivier Wong
• Is rate of return pricing a useful approach when value-based pricing is not appropriate? (RePEc:spr:eujhec:v:20:y:2019:i:7:d:10.1007_s10198-019-01032-7)
  by Michael Drummond & Adrian Towse
• Genetic screening, health care and the insurance industry (RePEc:spr:eujhec:v:5:y:2004:i:2:p:116-121)
  by Diego Ossa & Adrian Towse
• The desirability and feasibility of economic studies of drugs post-launch (RePEc:spr:eujhec:v:7:y:2006:i:1:p:5-6)
  by Michael Drummond & Anne Mason & Adrian Towse
• Operationalizing Value-Based Pricing of Medicines (RePEc:spr:pharme:v:31:y:2013:i:1:p:1-10)
  by Jon Sussex & Adrian Towse & Nancy Devlin
• Biosimilars: How Can Payers Get Long-Term Savings? (RePEc:spr:pharme:v:34:y:2016:i:6:d:10.1007_s40273-015-0380-x)
  by Jorge Mestre-Ferrandiz & Adrian Towse & Mikel Berdud
• Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases (RePEc:taf:apeclt:v:30:y:2023:i:16:p:2195-2199)
  by Dimitrios Kourouklis & Mikel Berdud & Mireia Jofre-Bonet & Adrian Towse
• Incentives for R&D for New Antimicrobial Drugs (RePEc:taf:ijecbs:v:18:y:2011:i:2:p:331-350)
  by Adrian Towse & Priya Sharma
• European Union Pharmaceutical Markets: A Case for Differential Pricing? (RePEc:taf:ijecbs:v:22:y:2015:i:2:p:263-275)
  by Adrian Towse & Michele Pistollato & Jorge Mestre-Ferrandiz & Zeba Khan & Satyin Kaura & Louis Garrison
• If it ain't broke, don't price fix it: the OFT and the PPRS (RePEc:wly:hlthec:v:16:y:2007:i:7:p:653-665)
  by Adrian Towse
• Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement (RePEc:wly:hlthec:v:24:y:2015:i:2:p:238-252)
  by Patricia M. Danzon & Andrew W. Mulcahy & Adrian K. Towse
• Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context (RePEc:wly:hlthec:v:24:y:2015:i:3:p:294-301)
  by Patricia Danzon & Adrian Towse & Jorge Mestre‐Ferrandiz
• The Political Economy of Healthcare. By David Resisman. MacMillan Press, London, 1993. No. of pages: 267. ISBN: 0‐333‐58579‐8 (RePEc:wly:hlthec:v:3:y:1994:i:5:p:347-348)
  by Adrian Towse
• Medical negligence and the NHS: an economic analysis (RePEc:wly:hlthec:v:8:y:1999:i:2:p:93-101)
  by Adrian Towse & Patricia Danzon